Dr. Reddy’s Laboratories announces the launch of Tetrabenazine Tablets in the U.S. Market
Posted on February 6,2018
Dr. Reddy’s Laboratories Ltd have announced that it has launched Tetrabenazine Tablets, a therapeutic equivalent generic version of Xenazine® (tetrabenazine) in the United States market approved by the U.S. Food and Drug Administration (USFDA).
The Xenazine® brand and generic had U.S. sales of approximately $322 million MAT for the most recent twelve months ending in November 2017 according to IMS Health*.
Dr. Reddy’s Tetrabenazine Tablets are available in strengths of 12.5 mg and 25 mg, each strength is available in a bottle count size of 112.
Xenazine® is a registered trademark of Valeant Pharmaceuticals Luxembourg S.A.R.L.